MX2017004618A - Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. - Google Patents

Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.

Info

Publication number
MX2017004618A
MX2017004618A MX2017004618A MX2017004618A MX2017004618A MX 2017004618 A MX2017004618 A MX 2017004618A MX 2017004618 A MX2017004618 A MX 2017004618A MX 2017004618 A MX2017004618 A MX 2017004618A MX 2017004618 A MX2017004618 A MX 2017004618A
Authority
MX
Mexico
Prior art keywords
heparan sulfate
diseases
treatment
biosynthesis inhibitors
sulfate biosynthesis
Prior art date
Application number
MX2017004618A
Other languages
English (en)
Inventor
Bhagwat Shripad
Wang Bing
R Luedtke Gregory
Spyvee Mark
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2017004618A publication Critical patent/MX2017004618A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

Se describen en la presente compuestos de la fórmula I, métodos de preparación de tales compuestos, composiciones farmacéuticas y medicamentos que contienen tales compuestos y métodos de uso de tales compuestos para tratar o prevenir enfermedades o condiciones que necesitan la inhibición de la biosíntesis de sulfato de heparano.
MX2017004618A 2014-10-09 2015-10-08 Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. MX2017004618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062036P 2014-10-09 2014-10-09
PCT/US2015/054761 WO2016057834A1 (en) 2014-10-09 2015-10-08 Heparan sulfate biosynthesis inhibitors for the treatment of diseases

Publications (1)

Publication Number Publication Date
MX2017004618A true MX2017004618A (es) 2017-10-23

Family

ID=55653801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004618A MX2017004618A (es) 2014-10-09 2015-10-08 Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.

Country Status (16)

Country Link
US (1) US20190151312A1 (es)
EP (1) EP3204009A4 (es)
JP (1) JP2017530991A (es)
KR (1) KR20170072242A (es)
CN (1) CN107106561A (es)
AR (1) AR102213A1 (es)
AU (1) AU2015330846A1 (es)
BR (1) BR112017006705A2 (es)
CA (1) CA2963607A1 (es)
IL (1) IL251497A0 (es)
MA (1) MA40957A (es)
MX (1) MX2017004618A (es)
RU (1) RU2017115305A (es)
TW (1) TW201629051A (es)
WO (1) WO2016057834A1 (es)
ZA (1) ZA201703003B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052395T2 (hu) 2015-09-11 2021-04-28 Sumitomo Dainippon Pharma Co Ltd Benzimidazol-származékok mint NAV 1.7 (nátriumcsatorna, feszültségkapuzott, IX típusú, alfa alegység (SCN9A) inhibitorok fájdalom, diszúria és szklerózis multiplex kezelésére
JP7160486B2 (ja) 2017-03-28 2022-10-25 ビーエーエスエフ ソシエタス・ヨーロピア 殺生物剤化合物
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
JP2020525525A (ja) 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
EP3421464B1 (en) 2017-06-30 2021-11-24 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
AU2018294054B2 (en) * 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN108997343A (zh) * 2018-04-17 2018-12-14 丁敏 一种治疗小儿热性惊厥的药物组合物的制备方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
US11053501B2 (en) 2018-11-30 2021-07-06 The Penn State Research Foundation Methods of treating neurodegenerative disease by inhibiting N-deacetylase N-sulfotransferase
CN114728940A (zh) * 2019-11-15 2022-07-08 日东制药株式会社 Glp-1受体激动剂及其用途
WO2021127282A1 (en) * 2019-12-18 2021-06-24 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2316831T3 (da) * 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
JP2013533883A (ja) * 2010-06-30 2013-08-29 アムジエン・インコーポレーテツド ＰＩ３Ｋδ阻害剤としての含窒素複素環化合物

Also Published As

Publication number Publication date
WO2016057834A9 (en) 2017-04-13
WO2016057834A1 (en) 2016-04-14
RU2017115305A (ru) 2018-11-14
CN107106561A (zh) 2017-08-29
JP2017530991A (ja) 2017-10-19
EP3204009A4 (en) 2018-05-23
CA2963607A1 (en) 2016-04-14
KR20170072242A (ko) 2017-06-26
IL251497A0 (en) 2017-05-29
TW201629051A (zh) 2016-08-16
MA40957A (fr) 2017-09-19
ZA201703003B (en) 2018-04-25
AU2015330846A1 (en) 2017-05-18
EP3204009A1 (en) 2017-08-16
US20190151312A1 (en) 2019-05-23
BR112017006705A2 (pt) 2017-12-26
AR102213A1 (es) 2017-02-15

Similar Documents

Publication Publication Date Title
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12016502352A1 (en) Pharmaceutical composition
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2019014773A (es) Inhibidores de ccl2.